Biogen (BIIB) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN US09062X1037
Biogen financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 9.89 bn USD |
| Gross profit | 7.49 bn USD |
| EBIT | 1.70 bn USD |
| Net income | 1.29 bn USD |
| Diluted EPS – continuing operations | 8.79 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
More stocks
- Centene Corporation (CNC)
- Schindler Holding AG (SCHP.SW)
- PTT Public Company Limited (PTT.BK)
- WEC Energy Group (WEC)
- Muyuan Foodstuff Co Ltd (002714.SZ)
- ResMed| (RMD)
- Ibiden Co Ltd (4062.T)
- Suzhou Dongshan Precision Manufacturing Co Ltd (002384.SZ)
- Hanwha Aerospace Co Ltd (012450.KS)
- Nutrien Ltd (NTR.TO)
- Bending Spoons S.p.A. Ordinary Shares (BSP)
- CEZ as (CEZ.PR)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.